Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
Haratake N, Hayashi H, Shimokawa M, Nakano Y, Azuma K, Oki M, Ota K, Yoshioka H, Sakamoto T, Yamamoto N, Nakagawa K, Seto T. Haratake N, et al. Among authors: shimokawa m. Clin Lung Cancer. 2022 May;23(3):e257-e263. doi: 10.1016/j.cllc.2021.10.007. Epub 2021 Oct 24. Clin Lung Cancer. 2022. PMID: 34887192 Clinical Trial.
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y. Toyokawa G, et al. Among authors: shimokawa m. Int J Clin Oncol. 2014 Aug;19(4):601-6. doi: 10.1007/s10147-013-0619-5. Epub 2013 Oct 26. Int J Clin Oncol. 2014. PMID: 24158772
Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.
Takenaka T, Takenoyama M, Yamaguchi M, Toyozawa R, Inamasu E, Kojo M, Toyokawa G, Yoshida T, Shiraishi Y, Morodomi Y, Hirai F, Taguchi K, Shimokawa M, Seto T, Ichinose Y. Takenaka T, et al. Among authors: shimokawa m. Eur J Cardiothorac Surg. 2015 Mar;47(3):550-5. doi: 10.1093/ejcts/ezu227. Epub 2014 Jun 3. Eur J Cardiothorac Surg. 2015. PMID: 24894095
Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M; CINV Study Group of Japan. Tamura K, et al. Among authors: shimokawa m. Int J Clin Oncol. 2015 Oct;20(5):855-65. doi: 10.1007/s10147-015-0786-7. Epub 2015 Feb 15. Int J Clin Oncol. 2015. PMID: 25681876
Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K. Takahama T, et al. Among authors: shimokawa m. Oncotarget. 2016 Sep 6;7(36):58492-58499. doi: 10.18632/oncotarget.11303. Oncotarget. 2016. PMID: 27542267 Free PMC article.
455 results